Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
The biotech company's revenues had fallen to as low as Rs 50 cr.
'No approval was given to Sputnik V on Thursday. Some queries have been asked on safety, efficacy, and logistics, which the firm will have answers to at the next meeting'
DRDO chief G Satheesh Reddy Reddy is the first Indian to be appointed Fellow of the Royal Institute of Navigation and of the Royal Aeronautical Society.
As remarkable as DRDO's contribution in containing and treating COVID-19 has been, its success over the last 15 months has been in its primary role of developing conventional defence equipment and technologies.
'It is extremely difficult to predict as to how many days it would take...But, as I had said that day, that they would decay in a few weeks, and majority of them have decayed'.
'Health will continue to be at the centre of the government's attention as it underpins economic recovery and our collective well being.'
The institute's incubation cell claims the start up mortality rate in the incubators are lowest.
The latest price revision includes mostly cardiovascular drugs, anti-bacterials, anti-herpes, contraceptives and gastrointestinal medicines
Indian loses chance to be research hub as domestic drug companies move R&D overseas.
Participants are eagerly waiting for the key macrodata -- IIP and CPI numbers due to be released later today.
Growth has been under pressure since the lockdowns related to Covid-19 started and fresh prescription generations slowed.
Polarisation and the increase in index weight of a few a stocks have weighed on performance. The worst performers include Nippon India Large Cap and HDFC Top 100 (2.6 per cent).
The top gainers on the Sensex are Gail(India), HDFC, Infosys.
'There is no emergency of a third wave that we are rushing for booster doses.'
Most Asian markets ended with gains.
The growth was led by family-owned companies and business groups with presence in pharmaceuticals, information technology services, and consumer products.
Better-than-expected financial results in Q3 due to higher revenue growth and margins in key markets fuel the rally
The company has entered into a tie-up with the US-based FSC Laboratories as its authorised generic partner for FSC's hypertension medicine Isoptin SR (Verapamil SR) in the US.
Once a difficult market to crack, in recent years, China has relatively opened up its drug market, enacting reforms and speeding up approval time.
Telecom stocks fell after Mukesh Ambani extended Reliance Jio's free offers till March 2017.
India on Monday successfully flight-tested its indigenously developed SMART torpedo system, which DRDO said will be a "game changer" in anti-submarine warfare, marking yet another milestone in strengthening the country's maritime strategic capabilities, defence sources said.
And when an inspector asked about the contents of unlabelled vials in the laboratory glassware washing area, a plant worker dumped them down a sink and said the contents could not be determined, according to a July 18 letter from the US Food and Drug Administration to Wockhardt, which makes sterile injectable drugs and various forms of insulin.
Dr Reddy's, Glenmark, Wockhardt have lined up alternatives for Zytiga
The progress of the GST Bill in Parliament is also likely to remain in focus
The Sensex ended below 28,000 for the second straight day at 27,869.
Russia's central bank early on Tuesday raised interest rates to 17 per cent to counter the 50 per cent rouble fall in six months.
Ajit Mishra, vice president, Research, Religare Broking, answers your stock market queries.
The conversion facilitated range enhancement and improvement in Pinaka's accuracy.
Financials were the top losers while oil shares also declined amid weak crude oil prices.
A longer shelf life is critical, given many makers have started manufacturing vaccines and stockpiling them, so as to make them available in the market immediately after approval, reports Sohini Das.
The S&P BSE Sensex ended 46 points lower at 24,824 and Nifty50 settled at 7,555, down by 8 points after hitting intra-day high of 7,600.45.
Hetero has priced the injectable drug at Rs 5,400 per 100 mg vial. With More drugmakers in line to launch the drug soon, the prices may see a further erosion.
Investment in market leaders with a safety-first approach could yield reasonable returns across sectors.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries
Almost each of these companies has a different technology to show for the effectiveness against microbes.
The S&P BSE Sensex plunged 301 points to close at 25,490 and the Nifty50 fell 86 points to end at 7,815.
SPI Cinemas will install Dolby Atmos in 37 screens across Chennai and Coimbatore.
